Pharmacogenetics of warfarin: A literature review

Pharmacogenetics of warfarin: A literature review

Warfarin is an oral indirect anticoagulant that is widely used for the prevention of thromboembolic events. Pharmacogenetic testing is the most promising approach to personalizing warfarin treatment. In this review, we aimed to summarize how the patients’ genetic predispositions affect the pharmacok...

Bibliográfalaš dieđut
Váldodahkkit:	Nadezhda V. Izmozherova, Muraz A. Shambatov, Artem A. Popov, Daria E. Zhuk, Viktoria A. Solodchenko
Materiálatiipa:	Artihkal
Giella:	English
Almmustuhtton:	Concilium Medicum 2024-11-01
Ráidu:	КардиоСоматика
Fáttát:	warfarin pharmacogenetics cyp2c9 vkorc1 cyp4f2
Liŋkkat:	https://cardiosomatics.ru/2221-7185/article/viewFile/631885/pdf

Geahča maid

Warfarin Pharmacogenetics: Challenges and Opportunities for Clinical Translation
Dahkki: Nita A Limdi, et al.
Almmustuhtton: (2012-10-01)

Pharmacogenetic Warfarin Dosing Algorithm in the Russian Population
Dahkki: T. A. Bairova, et al.
Almmustuhtton: (2019-07-01)

The Effect of CYP2C9 and VKORC1 Genetic Polymorphism on Warfarin Dose Requirements in a Sample of Iraqi Patients
Dahkki: Maha Ali Saleh, et al.
Almmustuhtton: (2021-03-01)

Effect of Gene-Based Warfarin Dosing on Anticoagulation Control and Clinical Events in a Real-World Setting
Dahkki: Jinhua Zhang, et al.
Almmustuhtton: (2020-01-01)

Should We Routinely Screen for Warfarin Gene Polymorphism in Patients with Coumadin Overdose?
Dahkki: Enes Elvin Gül, et al.
Almmustuhtton: (2016-12-01)

Pharmacogenetics of Anticoagulation and Clinical Events in Warfarin-Treated Patients: A Register-Based Cohort Study with Biobank Data and National Health Registries in Finland
Dahkki: Vuorinen AL, et al.
Almmustuhtton: (2021-03-01)

One Rare Warfarin Resistance Case and Possible Mechanism Exploration
Dahkki: Zhao L, et al.
Almmustuhtton: (2023-06-01)

Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians
Dahkki: Utama Andi, et al.
Almmustuhtton: (2011-06-01)

Identification of environmental and genetic factors that influence warfarin time in therapeutic range
Dahkki: Mariana R. Botton, et al.
Almmustuhtton: (2020-02-01)

APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA
Dahkki: D. A. Sychev, et al.
Almmustuhtton: (2015-09-01)

Association between Cytochrome P450 2 C9 and Vitamin K Epoxide Reductase Complex Subunit 1 Polymorphisms with Warfarin dose among Iranian Patients
Dahkki: Reyhaneh Kameli, et al.
Almmustuhtton: (2016-11-01)

The VKORC1 and CYP2C9 gene variants as pharmacogenetic factors in acenocoumarol therapy in Serbian patients - consideration of hypersensitivity and resistance
Dahkki: Rakićević Ljiljana, et al.
Almmustuhtton: (2022-01-01)

Evaluation of the VKORC 1 and CYP2C9 Gene Polymorphisms and Their Effects on the Emergency Complications in the Patients Using Warfarin
Dahkki: Oğuz Yardım, et al.
Almmustuhtton: (2017-06-01)

Hyper-responsiveness to warfarin in a young patient with the VKORC1 -1639GA/CYP2C9*1*46 genotype: a case report
Dahkki: Weam Aldiban, et al.
Almmustuhtton: (2022-10-01)

VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY
Dahkki: D. A. Sychev, et al.
Almmustuhtton: (2015-12-01)

The allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population
Dahkki: Fariba Emadian Razavi, et al.
Almmustuhtton: (2017-01-01)

Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy
Dahkki: Behzad Poopak, et al.
Almmustuhtton: (2016-02-01)

Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial
Dahkki: Nicholas L. Syn, et al.
Almmustuhtton: (2018-07-01)

Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response
Dahkki: J. E. Zhang, et al.
Almmustuhtton: (2017-05-01)

Treatment Adherence as a New Choice Factor for Optimization of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation and Hemostatic Gene Polymorphisms
Dahkki: Yu. P. Skirdenko, et al.
Almmustuhtton: (2016-11-01)

Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation
Dahkki: Jiao Li, et al.
Almmustuhtton: (2018-05-01)

Association Between ABCB1 Polymorphism and Stable Warfarin Dose Requirements in Brazilian Patients
Dahkki: Letícia C. Tavares, et al.
Almmustuhtton: (2018-05-01)

Genotype-phenotype correlations in patients treated with acenocoumarol / Corelaţii genotip-fenotip la pacienţii trataţi cu acenocumarol
Dahkki: Militaru Florentina Claudia, et al.
Almmustuhtton: (2014-09-01)

Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard
Dahkki: Mohammad A. Alshabeeb, et al.
Almmustuhtton: (2022-08-01)

VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY
Dahkki: D. A. Sychev, et al.
Almmustuhtton: (2015-12-01)

PHARMACOGENETICS OF ANTITHROMBOTIC DRUGS: STATUS UPDATE ON THE PROBLEM
Dahkki: Ekaterina S. Kropacheva
Almmustuhtton: (2018-12-01)

CLOPIDOGREL PHARMACOGENETICS
Dahkki: A. N. Meshkov
Almmustuhtton: (2016-01-01)

Methylation of CYP1A1 and VKORC1 promoter associated with stable dosage of warfarin in Chinese patients
Dahkki: Shiwei He, et al.
Almmustuhtton: (2021-06-01)

NEW APPROACHES TO INDIVIDUALIZED CHOICE OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION
Dahkki: Ju. P. Skirdenko, et al.
Almmustuhtton: (2018-03-01)

FREQUENCIES OF POLYMORPHISMS IN THE CYTOCHROME’S P450 GENES OF WARFARIN TRANSFORMATION IN A EUROPEAN POPULATION OF EASTERN SIBERIA
Dahkki: T. A. Bairova, et al.
Almmustuhtton: (2018-09-01)

A case of a warfarinized renal cancer patient monitored for prothrombin time-international normalized ratio during methadone introduction
Dahkki: Kaoru Yoshioka, et al.
Almmustuhtton: (2017-06-01)

Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions
Dahkki: Jeiziner C, et al.
Almmustuhtton: (2021-02-01)

CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
Dahkki: Nizamuddin S, et al.
Almmustuhtton: (2021-01-01)

Determination of Pleiotropic Effect of Warfarin in VKORC1 and CYP2C9 Genotypes in Patients With Heart Valve Replacement
Dahkki: Huma Shafique, et al.
Almmustuhtton: (2022-06-01)

Warfarin therapy in patients with coronary heart disease and atrial fibrillation: drug interactions and genetic sensitivity to warfarin
Dahkki: O. A. Panibratiuk, et al.
Almmustuhtton: (2020-06-01)

Factors influencing vitamin K antagonists therapy / Factori care influențează terapia cu antagoniști ai vitaminei K
Dahkki: Brudașcă Ioana
Almmustuhtton: (2015-06-01)

APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA
Dahkki: D. A. Sychev, et al.
Almmustuhtton: (2015-09-01)

Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors
Dahkki: Zhu YT, et al.
Almmustuhtton: (2020-05-01)

GENETIC POLYMORPHISM OF CYTOCHROMES P450 2C9 AND 2C19 IN SLOVENIAN POPULATION
Dahkki: Darja Herman, et al.
Almmustuhtton: (2003-06-01)

Clinical significance of the series of CYP2C9*non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population
Dahkki: Dongxu Wang, et al.
Almmustuhtton: (2022-11-01)